MDXH vs. LAB, TALK, BFLY, TBRG, OM, HCAT, SOPH, NYXH, KRMD, and CCLD
Should you be buying MDxHealth stock or one of its competitors? The main competitors of MDxHealth include Standard BioTools (LAB), Talkspace (TALK), Butterfly Network (BFLY), TruBridge (TBRG), Outset Medical (OM), Health Catalyst (HCAT), SOPHiA GENETICS (SOPH), Nyxoah (NYXH), KORU Medical Systems (KRMD), and CareCloud (CCLD). These companies are all part of the "medical info sys" industry.
MDxHealth vs. Its Competitors
Standard BioTools (NASDAQ:LAB) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.
MDxHealth has a net margin of -34.98% compared to Standard BioTools' net margin of -69.08%. Standard BioTools' return on equity of -20.23% beat MDxHealth's return on equity.
53.7% of Standard BioTools shares are held by institutional investors. 23.2% of Standard BioTools shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
MDxHealth has lower revenue, but higher earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
In the previous week, Standard BioTools had 2 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Standard BioTools and 3 mentions for MDxHealth. MDxHealth's average media sentiment score of 1.72 beat Standard BioTools' score of 1.46 indicating that MDxHealth is being referred to more favorably in the news media.
Standard BioTools presently has a consensus price target of $1.55, suggesting a potential upside of 21.09%. MDxHealth has a consensus price target of $7.00, suggesting a potential upside of 101.15%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Standard BioTools.
Standard BioTools has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.
Summary
Standard BioTools and MDxHealth tied by winning 8 of the 16 factors compared between the two stocks.
Get MDxHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MDxHealth Competitors List
Related Companies and Tools
This page (NASDAQ:MDXH) was last updated on 9/10/2025 by MarketBeat.com Staff
Free MDXH Stock Alerts